| [1] | Salive M.E., Tjaden A.H., Ames J.R., et al. (2026). Lifestyle and metformin interventions and risk of multimorbidity in adults with prediabetes. JAMA. Published online June 15, 2026. DOI:10.1001/jama.2026.8492 |
| [2] | Gong Q, Zhang P, Wang J, et al. (2019). Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the da qing diabetes prevention outcome study. Lancet Diabetes Endocrinol. 7:452−461. DOI:10.1016/S2213-8587(19)30093-2 |
| [3] | Kulkarni AS, Gubbi S, and Barzilai N. (2020). Benefits of metformin in attenuating the hallmarks of aging. Cell Metab. 32:15−30. DOI:10.1016/j.cmet.2020.04.001 |
| [4] | Kroemer G, Maier A.B., Cuervo A.M., et al. (2025). From geroscience to precision geromedicine: Understanding and managing aging. Cell 188:2043−2062. DOI:10.1016/j.cell.2025.03.011 |
| [5] | Lincoff A.M., Brown-Frandsen K, Colhoun H.M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 389:2221−2232. DOI:10.1056/NEJMoa2307563 |
| Luo G., Ding D., Liu M., et al. (2026). Beyond glucose: How early lifestyle intervention rewires the long-term trajectory of multimorbidity and healthy aging. The Innovation Nutrition 1:100032. https://doi.org/10.59717/j.xinn-nutri.2026.100032 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Proposed framework illustrating how early lifestyle intervention extends beyond glucose control to reshape the long-term trajectory of multimorbidity and healthy aging, compared with metformin.